Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Oncol Ther
.
2024 Mar;12(1):13-17.
doi: 10.1007/s40487-023-00249-0.
Epub 2023 Nov 14.
Authors
Heidi Ko
1
,
Rebecca A Previs
2
3
,
Kyle C Strickland
2
4
,
Jonathan Klein
2
,
Brian Caveney
2
,
Chiara Chiruzzi
5
,
Marcia Eisenberg
2
,
Eric A Severson
2
,
Shakti Ramkissoon
2
6
,
Kamal S Saini
7
8
Affiliations
1
Labcorp Oncology, Durham, NC, 27560, USA.
[email protected]
.
2
Labcorp Oncology, Durham, NC, 27560, USA.
3
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC, USA.
4
Department of Pathology, Duke University Medical Center, Duke Cancer Institute, Durham, NC, 27710, USA.
5
Fortrea Inc, Durham, NC, USA.
6
Wake Forest Comprehensive Cancer Center and Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, 27109, USA.
7
Fortrea Inc, Durham, NC, USA.
[email protected]
.
8
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
[email protected]
.
PMID:
37962832
PMCID:
PMC10881909
DOI:
10.1007/s40487-023-00249-0
No abstract available
Keywords:
HER2 testing; HER2-directed antibody–drug conjugate; HER2-low; Metastatic breast cancer.
Publication types
Editorial